Overview

  • Product nameAnti-VEGFA antibody
    See all VEGFA primary antibodies
  • Description
    Rabbit polyclonal to VEGFA
  • Tested applicationsSuitable for: Sandwich ELISA, WB, Indirect ELISAmore details
  • Species reactivity
    Reacts with: Rat
  • Immunogen

    Recombinant full length protein corresponding to Rat VEGFA.

Properties

Applications

Our Abpromise guarantee covers the use of ab70612 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Sandwich ELISA
WB
Indirect ELISA
  • Application notesI-ELISA: Use at a concentration of 0.5 - 2.0 µg/ml. Used in conjunction with compatible secondary reagents, ab70612 allows the detection of at least 0.2 - 0.4 ng/well of recombinant Rat VEGF.

    sELISA: Use at a concentration of 0.5 - 2.0 µg/ml.

    WB: Use at a concentration of 0.1 - 0.2 µg/ml. Predicted molecular weight: 27 kDa. Used in conjunction with compatible secondary reagents the detection limit for recombinant Rat VEGF is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionGrowth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.
    • Tissue specificityIsoform VEGF189, isoform VEGF165 and isoform VEGF121 are widely expressed. Isoform VEGF206 and isoform VEGF145 are not widely expressed.
    • Involvement in diseaseDefects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:603933]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
    • Sequence similaritiesBelongs to the PDGF/VEGF growth factor family.
    • Cellular localizationSecreted. VEGF121 is acidic and freely secreted. VEGF165 is more basic, has heparin-binding properties and, although a signicant proportion remains cell-associated, most is freely secreted. VEGF189 is very basic, it is cell-associated after secretion and is bound avidly by heparin and the extracellular matrix, although it may be released as a soluble form by heparin, heparinase or plasmin.
    • Information by UniProt
    • Database links
    • Alternative names
      • MGC70609 antibody
      • MVCD1 antibody
      • Vascular endothelial growth factor A antibody
      • vascular endothelial growth factor antibody
      • Vascular permeability factor antibody
      • VEGF A antibody
      • Vegf antibody
      • VEGF-A antibody
      • VEGF120 antibody
      • Vegfa antibody
      • VEGFA_HUMAN antibody
      • VPF antibody
      see all

    References for Anti-VEGFA antibody (ab70612)

    ab70612 has not yet been referenced specifically in any publications.

    Product Wall

    Thank you for contacting us.

    We do actually recommend storing the lyophilised antibody at -20C for long term storage; this will be stable for 2 years.

    The antibody should be stored lyophilised at -20C till use and then reconstituted...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"